2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, T. K, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology 2021, 5: 1432-1442. PMID: 34527850, PMCID: PMC8437220, DOI: 10.1200/po.20.00439.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinDNA DamageFemaleHumansIndolesMaleMiddle AgedMorpholinesNeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsProtein Kinase InhibitorsPyrimidinesSulfonamidesConceptsHigh-grade serous ovarian cancerComplete responseResponse rateClinical benefit ratePartial response ratePrimary end pointOverall response rateHomologous recombination repair deficiencySerous ovarian cancerPoly (ADP-ribose) polymerase (PARP) inhibitorsPrior therapyUnacceptable toxicityEntire cohortRefractory cancerBenefit rateOvarian cancerPromising therapyPatientsBasket trialsDay 1End pointOlaparibPolymerase inhibitorsTherapyAdditional studies
1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.
Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. JAMA Dermatology 1988, 124: 878-84. PMID: 3288124, DOI: 10.1001/archderm.124.6.878.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationCarmustineCisplatinCombined Modality TherapyCyclophosphamideFemaleHumansLiver NeoplasmsLung NeoplasmsMaleMelanomaMelphalanMiddle AgedPelvic NeoplasmsRemission InductionConceptsAutologous bone marrow supportBone marrow supportHigh-dose combinationMarrow supportAgent chemotherapyPhase 2 doseMetastatic malignant melanomaOverall response rateMedian survivalComplete responsePartial responseSurgical resectionAdditional patientsMedian timeResidual tumorTreatment courseMalignant melanomaMarrow reconstitutionChemotherapyToxic reactionsPatientsResponse rateEntire groupMonthsDisease
1987
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Journal Of The National Cancer Institute 1987, 71: 119-25. PMID: 3542208.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBreast NeoplasmsCarmustineCisplatinCombined Modality TherapyCyclophosphamideDrug EvaluationFemaleHematologic DiseasesHumansMelanomaMelphalanMiddle AgedNeoplasm MetastasisNeoplasmsStatistics as TopicConceptsVeno-occlusive diseaseEvaluable patientsBreast cancerPrior treatmentAutologous bone marrow supportDose-limiting toxic effectFatal veno-occlusive diseaseCourses of cyclophosphamideDose level 4Bone marrow supportGood partial responseHigh-dose combinationDose level 5Metastatic breast cancerThree-drug combinationPolymorphonuclear leukocyte countAddition of melphalanHighest dose levelToxic effectsMarrow reinfusionMarrow supportPreparative regimenMost patientsPartial responseTransfusion independence
1986
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. Journal Of Clinical Oncology 1986, 4: 1592-7. PMID: 3534155, DOI: 10.1200/jco.1986.4.11.1592.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAlkylating AgentsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBreast NeoplasmsCarmustineCisplatinCombined Modality TherapyCyclophosphamideDrug EvaluationFemaleHumansMiddle AgedNeoplasm MetastasisConceptsAutologous bone marrow supportBone marrow supportInflammatory breast cancerMetastatic breast cancerPartial responseComplete responseBreast cancerPrior chemotherapyMarrow supportTumor regressionHigh-dose combination chemotherapy regimenMetastatic breast cancer patientsHigher partial responsePhase II regimenPrior combination chemotherapyHigh-dose regimenHigh-dose combinationCombination chemotherapy regimenBreast cancer patientsBone marrow harvestEvaluable patientsChemotherapy regimenAgent chemotherapyFirst recurrenceMedian survival